Registration is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event Titled ''The Road To Revenue: Modular Medical's Strategy For Launching Pivot'' Featuring Modular Medical CEO - Friday, September 4, 2026

Modular Medical CEO Jeb Besser highlighted The Pivot tubeless patch pump, a wearable insulin delivery platform offering continuous subcutaneous infusion with basal and bolus insulin over a three-day wear period. The company positions it as a differentiated solution for insulin-dependent adults still using multiple daily injections, citing a multi-billion-dollar market opportunity. No financial guidance or performance metrics were provided in the excerpt.

Analysis

This is more of a category-optionality event than a near-term revenue event. If the platform is real and reimbursable, the first beneficiaries are not just the company but the entire insulin-device market: a simpler form factor can expand penetration among patients who have resisted traditional pumps, which is incremental demand rather than pure share theft. The first-order losers would be incumbent pump makers such as PODD, TNDM, and to a lesser extent MDT’s diabetes franchise, but the bigger second-order effect is pricing pressure in the "good-enough" segment where ease of use matters more than feature depth.

The key issue is timing. Any commercial impact is likely 12-24 months out and gated by regulatory, payer, and distribution execution, while the stock can move on much shorter promotional bursts. For a microcap like MODD, the market is likely to trade the story ahead of evidence, which makes financing risk central: repeated investor marketing without conversion metrics usually ends in dilution before scale. The thesis is falsified if the company cannot show payer coverage, durable reorder rates, or a clear path to manufacturing scale over the next 2-3 quarters.

Contrarian view: consensus may be underestimating how large the MDI conversion pool is, but may also be overestimating how much of that pool is addressable by a new entrant with limited reimbursement leverage. The real battleground is not device specs; it is channel friction, educator bandwidth, and whether endocrinologists adopt a new system when incumbent ecosystems already have sticky workflows. If this platform works, it is a long-duration category expansion story; if not, it is a promotion-driven rally with poor follow-through.

Key Decisions for Investors

• No immediate directional trade in MODD until there is hard evidence on reimbursement, manufacturing, or first commercial orders; treat current move as promotional and high risk of reversal.
• Set an alert on MODD for any 8-K / investor update that includes payer coverage, launch dates, or gross margin targets; that is the first point where the story becomes investable.
• Watch PODD and TNDM as the cleaner expression of any competitive-share concern; if MODD gains traction, expect the market to pressure lower-end pump multiples before revenue impact shows up.
• If forced into a relative-value trade, prefer short-duration hedges against the diabetes-device subsector rather than outright short MODD; financing/dilution risk can dominate stock-specific fundamentals in the next 1-2 quarters.
• Falsify the bullish thesis if management cannot demonstrate a credible path to scale within 2-3 quarters or if launch commentary is not followed by third-party validation from clinics or payers.